1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1 An Overview of Drug Bioavailability
3.2 Need of Bioavailability Enhancement
3.3 Evolution of Bioavailability Enhancement Technologies
3.4 Studies for Assessment of Bioavailability
3.4.1 Study Design
3.4.1.1. Absolute Bioavailability
3.4.1.2. Relative Bioavailability
3.4.1.3. Single vs Multiple Dose Study
3.4.1.4. Healthy Subjects vs Patients
3.4.2. Assessment Methods
3.5. Factors Affecting Bioavailability
3.5.1. Drug Related Factors
3.5.2. Body Related Factors
3.6. Bioavailability Enhancement Technologies
3.6.1. Physical Technologies
3.6.1.1. Solid Dispersion
3.6.1.2. Nanosuspension Technology
3.6.2. Chemical Technologies
3.6.2.1. Lipid Based Formulations
3.6.2.2. Metal Based Drug Delivery System
3.6.2.3. Polymer Based Drug Delivery System
3.6.3. Biological Technologies
3.7. Trends in Bioavailability Enhancement
3.7.1. Need for Outsourcing Bioavailability Enhancement Requirements

4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Bioavailability Enhancement: List of Service Providers
4.2.1. Distribution by Company Portfolio
4.2.2. Distribution by Geographical Location
4.2.3. Distribution by Company Size
4.2.4. Distribution by Year of Establishment
4.2.5. Distribution by Bioavailability Enhancement Principle
4.2.6. Distribution by Bioavailability Enhancement Approach
4.2.6.1. Distribution by Lipid Based Approaches
4.2.6.2. Distribution by Size Reduction Approaches
4.2.6.3. Distribution by Solid Dispersion Approaches
4.2.6.4. Distribution by Other Approaches
4.2.7. Distribution by Dosage Form
4.2.8. Distribution by Route of Administration
4.2.9. Heat Map Analysis of Service Providers
4.2.10. Distribution by Leading Players

5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Lonza
5.2.1. Company Overview
5.2.2. Financial Performance
5.2.3. Services Portfolio
5.2.4. Bioavailability Enhancement Services Portfolio
5.2.5. Recent Partnerships
5.2.6. Future Outlook
5.3. Catalent
5.3.1 Company Overview
5.3.2 Financial Performance
5.3.3 Services Portfolio
5.2.4. Bioavailability Enhancement Services Portfolio
5.2.5. Recent Partnerships
5.2.6. Future Outlook
5.4. Ascendia Pharmaceuticals
5.4.1. Company Overview
5.4.2. Services Portfolio
5.4.3. Bioavailability Enhancement Services Portfolio
5.4.4. Future Outlook
5.5. Particle Sciences (Acquired by Lubrizol)
5.4.1. Company Overview
5.4.2. Financial Performance
5.4.3. Services Portfolio
5.4.4. Bioavailability Enhancement Services Portfolio
5.4.5. Recent Partnerships
5.4.6. Future Outlook
5.6. Juniper Pharma Services
5.6.1. Company Overview
5.6.2. Financial Performance
5.6.3. Services Portfolio
5.6.4. Bioavailability Enhancement Services Portfolio
5.6.5. Recent Partnerships
5.6.6. Future Outlook
5.7. Phosphorex
5.7.1. Company Overview
5.7.2. Financial Performance
5.7.3. Services Portfolio
5.7.4. Bioavailability Enhancement Services Portfolio
5.7.5. Recent Partnerships
5.7.6. Future Outlook
5.8. Kuecept (Acquired by Aptuit / Evotec)
5.8.1. Company Overview
5.8.2. Financial Performance
5.8.3. Services Portfolio
5.8.4. Bioavailability Enhancement Services Portfolio
5.8.5. Recent Partnerships
5.8.6. Future Outlook
5.9. Creative Biolabs
5.9.1. Company Overview
5.9.2. Financial Performance
5.9.3. Services Portfolio
5.9.4. Bioavailability Enhancement Services Portfolio
5.9.5. Recent Partnerships
5.9.5. Future Outlook
5.10. WuXi AppTec
5.10.1. Company Overview
5.10.2. Financial Performance
5.10.3. Services Portfolio
5.10.4. Bioavailability Enhancement Services Portfolio
5.10.5. Recent Partnerships
5.10.6. Future Outlook

6. BENCHMARK ANALYSIS
6.1. Chapter Overview
6.2. Benchmark Analysis: Methodology
6.3. Benchmark Analysis: Peer Groups
6.3.1. Benchmark Analysis: North and South America, Peer Group I
6.3.2. Benchmark Analysis: North and South America, Peer Group II
6.3.3. Benchmark Analysis: North and South America, Peer Group III
6.3.4. Benchmark Analysis: Europe, Peer Group IV
6.3.5. Benchmark Analysis: Europe, Peer Group V
6.3.6. Benchmark Analysis: Asia-Pacific, Peer Group VI
6.3.7. Benchmark Analysis: Asia-Pacific, Peer Group VII

7. PARTNERSHIPS AND COLLABORATIONS
7.1. Chapter Overview
7.2. Types of Partnerships
7.3. Bioavailability Enhancement: Analysis of Partnerships
7.3.1. Distribution by Year of Partnerships
7.3.2. Distribution by Type of Partnerships
7.3.3. Distribution by Most Active Companies
7.3.4. Distribution by Leading Acquirers

8. PUBLICATION ANALYSIS
8.1. Chapter Overview
8.2. Bioavailability Enhancement: Analysis of Publications
8.2.1. Distribution by Year of Publications
8.2.2. Distribution by Key Journals
8.2.3. Emerging Areas: Word Clouds
8.2.4. Analysis be Key Approaches
8.2.4.1. Distribution by Number of Publications
8.2.4.2. Distribution by Year of Publications
8.2.4.3. Distribution by Growth Rate
8.2.4.4. Bubble Chart Analysis
8.2.5. Distribution by Leading Publications

9. PATENT ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Bioavailability Enhancement: Analysis of Patents
9.3.1. Distribution by Publication Year
9.3.2. Distribution by Geographical Location
9.3.3. Distribution by CPC Classification
9.3.4. Emerging Areas: Word Cloud
9.3.5. Patent Valuation
9.3.6 Leading Citations

10. CLINICAL TRIALS ANALYSIS
10.1. Chapter Overview
10.2. Guidelines to Conduct Bioavailability Studies
10.3. Clinical Trials Analysis
10.3.1. Research Methodology
10.3.2. Distribution by Study Start Date
10.3.3. Distribution by Study Design
10.3.4. Distribution by Phase
10.3.5. Distribution by Trial Status
10.3.6. Distributions of Types of Molecules by Phase of Development
10.3.7. Distribution by Leading Players
10.3.8. Study Focus: Word Cloud

11. DEMAND ANALYSIS
11.1. Chapter Overview
11.2. Bioavailability Enhancement Opportunities
11.3. Research Methodology
11.4. Demand Analysis: New Chemical Entities (NCEs)
11.5. Demand Analysis: Generics

12. MARKET FORECAST
12.1. Chapter Overview
12.2. Forecast Methodology
12.3. Overall Bioavailability Enhancement Market, 2018-2030
12.4. Bioavailability Enhancement Market: Distribution by BCS Classification
12.4.1. Bioavailability Enhancement Market by BCS II Drugs
12.4.2. Bioavailability Enhancement Market by BCS IV Drugs
12.5. Bioavailability Enhancement Market: Distribution by Type of Bioavailability Enhancement Approach
12.5.1. Bioavailability Enhancement Market by Lipid Based Approaches
12.5.2. Bioavailability Enhancement Market by Size Reduction Based Approaches
12.5.3. Bioavailability Enhancement Market by Solid Dispersion Based Approaches
12.5.4. Bioavailability Enhancement Market by Other Bioavailability Enhancement Approaches
12.6. Bioavailability Enhancement Market: Distribution by Geographical Location
12.6.1. Bioavailability Enhancement Market in the Americas (North America / South America)
12.6.2. Bioavailability Enhancement Market in Europe
12.6.3. Bioavailability Enhancement Market in Asia-Pacific
12.6.4. Bioavailability Enhancement Market in Rest of the World

13. CONCLUSION
13.1. Challenges Associated with Low Solubility and Permeability of Drugs Has Led to Increasing Demand for Bioavailability Enhancement
13.2. The Market is Characterized by The Presence of Several Established Players, As Well As Small and Mid-Sized Companies in Different Geographies
13.3. Size Reduction, Solid Dispersion and Lipid Based Methods are Offered by Several Technology / Service Providers; Players Offering Other Approaches are Also Emerging
13.4. The Field Has Witnessed Increasing Partnership Activity As Multiple Players are Collaborating for Expanding Capabilities
13.5. Ongoing Advances Have Led to Rapid Innovation and Increase in Patent Filling Activity
13.6. The Rising Number of BCS II and BCS IV Drugs and Increasing Adoption of Different Approaches for Enhancement of Drug Bioavailability is Likely to Foster the Long-Term Growth

14. TRANSCRIPTS OF PUBLIC DISCUSSIONS
14.1. Chapter Overview
14.2. David Vodak, Vice President of Chemistry, Bend Research
14.3. John K Tilloston, Pharmaceutical and Nutritional Technical Business Director, ABITEC
14.4. Kaspar van den Dries, Senior Director Formulation Sciences and Martin Piest, Senior Formulation Scientist, Patheon
14.5. Anonymous, MilliporeSigma Process Solutions
14.6. Brent Moody, Principal Scientist, Science and Technology, Catalent Pharma Solutions
14.7. Anonymous, Sancilio Pharmaceuticals
14.8. Frank Romanski, BASF Pharma Solutions
14.9. Karl Kolter, BASF Pharma Solutions

15. APPENDIX 1: TABULAR DATA

16. APPENDIX 2: LIST OF COMPANIES

List of Tables
Table 3.1 Solid Dispersion Method: List of Drugs
Table 3.2 Nanoparticles: List of Drugs
Table 3.3 Nanosuspensions: List of Drugs
Table 3.4 Liposome Based Formulations: List of Drugs
Table 3.5 Micelles Based Formulations: List of Drugs
Table 3.6 Micro-Emulsion Based Parenteral Formulations: List of Drugs
Table 3.7 Micro-Emulsion Based Oral Formulations: List of Drugs
Table 3.8 Lipid Based Oral Formulations: List of Drugs
Table 3.9 Metal Based Drug Delivery Approaches: List of Drugs
Table 3.10 Polymer Based Drug Delivery Approaches: List of Drugs
Table 3.11 Biological Formulation Technologies: List of Drugs
Table 4.1 Bioavailability Enhancement Service Providers: Information on Company Portfolio
Table 4.2 Bioavailability Enhancement Service Providers: Information on Bioavailability Enhancement Approaches
Table 4.3 Bioavailability Enhancement Service Providers: Information on Lipid Based Approaches
Table 4.4 Bioavailability Enhancement Service Providers: Information on Size Reduction Approaches
Table 4.5 Bioavailability Enhancement Service Providers: Information on Solid Dispersion Based Approaches
Table 4.6 Bioavailability Enhancement Service Providers: Information on Other Approaches
Table 5.1 Lonza: Future Outlook
Table 5.2 Catalent: Future Outlook
Table 5.3 Catalent: List of Upcoming Conferences
Table 5.4 Ascendia Pharmaceuticals: Future Outlook
Table 5.5 Particle Sciences: Future Outlook
Table 5.6 Juniper Pharma Services: Future Outlook
Table 5.7 Phosphorex: Future Outlook
Table 5.8 Creative Biolabs: Future Outlook
Table 5.9 WuXi AppTec: Future Outlook
Table 6.1 Benchmark Analysis: Peer Groups
Table 7.1 Bioavailability Enhancement: Partnerships, 2013-2018
Table 8.1 Bioavailability Enhancement: Leading Publications
Table 9.1 Bioavailability Enhancement Patents: Most Popular CPC Symbols
Table 9.2 Bioavailability Enhancement Patents: List of Top CPC Classifications
Table 9.3 Bioavailability Enhancement Patents: List of Top Leading Patents
Table 10.1 Bioavailability Studies: Regulatory Guidelines and Methodologies
Table 14. 1 Technology Selection for Enhancing Bioavailability
Table 15.1 Bioavailability Enhancement Service Providers: Distribution by Type of Bioavailability Approach and Geography
Table 15.2 Bioavailability Enhancement Service Providers: Distribution by Company Size
Table 15.3 Bioavailability Enhancement Service Providers: Cumulative Distribution by Year of Establishment
Table 15.4 Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Principle
Table 15.5 Bioavailability Enhancement Service Providers: Distribution by the Type of Approach
Table 15.6 Bioavailability Enhancement Service Providers: Distribution by Lipid Based Approaches
Table 15.7 Bioavailability Enhancement Service Providers: Distribution by Size Reduction Approaches
Table 15.8 Bioavailability Enhancement Service Providers: Distribution by Solid Dispersion Based Approaches
Table 15.9 Bioavailability Enhancement Service Providers: Distribution by Other Formulation Approaches
Table 15.10 Bioavailability Enhancement Service Providers: Distribution by Dosage Form
Table 15.11 Bioavailability Enhancement Service Providers: Distribution by Route of Administration
Table 15.12 Bioavailability Enhancement Service Providers: Heat Map Analysis by Dosage Form and Bioavailability Enhancement Approaches
Table 15.13 Lonza: Annual Revenues, 2013-2017 (CHF Billion)
Table 15.14 Catalent: Annual Revenues, 2013- 2017 (USD Billion)
Table 15.15 Catalent: Revenues by Product Types, 2017 (USD Million)
Table 15.16 Juniper Pharmaceuticals: Annual Revenues, 2013-2017 (USD Million)
Table 15.17 WuXi AppTec: Annual Revenues, 2010-Q3 2015 (USD Million)
Table 15.18 Benchmark Analysis: Distribution of Industry Players by Year of Establishment and Geographical Location
Table 15.19 Benchmark Analysis, Peer Group I: Distribution by Bioavailability Enhancement Principle
Table 15.20 Benchmark Analysis, Peer Group I: Distribution by Type of Bioavailability Approach
Table 15.21 Benchmark Analysis, Peer Group I: Distribution by Dosage Form
Table 15.22 Benchmark Analysis, Peer Group I: Distribution by Route of Administration
Table 15.23 Benchmark Analysis, Peer Group II: Distribution by Bioavailability Enhancement Principle
Table 15.24 Benchmark Analysis, Peer Group II: Distribution by Bioavailability Enhancement Approach
Table 15.25 Benchmark Analysis, Peer Group II: Distribution by Dosage Form
Table 15.26 Benchmark Analysis, Peer Group II: Distribution by Route of Administration
Table 15.27 Benchmark Analysis, Peer Group III: Distribution by Bioavailability Enhancement Principle
Table 15.28 Benchmark Analysis, Peer Group III: Distribution by Bioavailability Enhancement Approach
Table 15.29 Benchmark Analysis, Peer Group III: Distribution by Dosage Form
Table 15.30 Benchmark Analysis, Peer Group III: Distribution by Route of Administration
Table 15.31 Benchmark Analysis, Peer Group IV: Distribution by Bioavailability Enhancement Principle
Table 15.32 Benchmark Analysis, Peer Group IV: Distribution by Bioavailability Enhancement Approach
Table 15.33 Benchmark Analysis, Peer Group IV: Distribution by Dosage Form
Table 15.34 Benchmark Analysis, Peer Group IV: Distribution by Route of Administration
Table 15.35 Benchmark Analysis, Peer Group V: Distribution by Bioavailability Enhancement Approach
Table 15.36 Benchmark Analysis, Peer Group V: Distribution by Approach Type
Table 15.37 Benchmark Analysis, Peer Group V: Distribution by Dosage Form
Table 15.38 Benchmark Analysis, Peer Group V: Distribution by Route of Administration
Table 15.39 Benchmark Analysis, Peer Group VI: Distribution by Bioavailability Enhancement Principle
Table 15.40 Benchmark Analysis, Peer Group VI: Distribution by Bioavailability Enhancement Approach
Table 15.41 Benchmark Analysis, Peer Group VI: Distribution by Dosage Form
Table 15.42 Benchmark Analysis, Peer Group VI: Distribution by Route of Administration
Table 15.43 Benchmark Analysis, Peer Group VII: Bioavailability Enhancement Principle
Table 15.44 Benchmark Analysis, Peer Group VII: Distribution by Bioavailability Enhancement Approach
Table 15.45 Benchmark Analysis, Peer Group VII: Distribution by Dosage Form
Table 15.46 Benchmark Analysis, Peer Group VII: Distribution by Route of Administration
Table 15.47 Benchmark Analysis, Peer Group VIII: Distribution by Bioavailability Enhancement Principle
Table 15.48 Benchmark Analysis, Peer Group VIII: Distribution by Bioavailability Enhancement Approach
Table 15.49 Benchmark Analysis, Peer Group VIII: Distribution by Dosage Form
Table 15.50 Benchmark Analysis, Peer Group VIII: Distribution by Route of Administration
Table 15.51 Bioavailability Enhancement Partnerships: Cumulative Year-wise Trend
Table 15.52 Bioavailability Enhancement Partnerships: Distribution by Type of Collaboration
Table 15.53 Bioavailability Enhancement Partnerships: Distribution by Most Active Players
Table 15.54 Bioavailability Enhancement Partnerships: Distribution by Leading Acquirers
Table 15.55 Bioavailability Enhancement Publications: Cumulative Year-Wise Trend
Table 15.56 Bioavailability Enhancement Publications: Top 15 Journals
Table 15.57 Bioavailability Enhancement Publications: Distribution of Approaches by Number of Publications
Table 15.58 Bioavailability Enhancement Publications: Year-Wise Technology Distribution
Table 15.59 Bioavailability Enhancement Publications: Distribution of Approaches by CAGR (2008-2017)
Table 15.60 Bioavailability Enhancement Publications: Bubble Analysis
Table 15.61 Bioavailability Enhancement Publications: Distributions of Top Publications by Technology
Table 15.62 Bioavailability Enhancement Patents: Distribution by Type of Patent
Table 15.63 Bioavailability Enhancement Patents: Distribution by Type of Approach
Table 15.64 Bioavailability Enhancement Patents: Cumulative Distribution by Publication Years for Bioavailability Enhancement Approaches
Table 15.65 Bioavailability Enhancement Patents: Distribution by Bioavailability Enhancement Approach and Patent CAGR
Table 15.66 Bioavailability Enhancement Patents: Distribution by Publication Year
Table 15.67 Bioavailability Enhancement Patents: Year-Wise Regional Distribution
Table 15.68 Bioavailability Enhancement Patents: Age of Patent
Table 15.69 Bioavailability Enhancement Patents: Patent Valuation
Table 15.70 Bioavailability Studies: Cumulative Year Wise Trend
Table 15.71 Bioavailability Studies: Intervention of Study
Table 15.72 Bioavailability Studies: Purpose of Study
Table 15.73 Bioavailability Studies: Allocation of Study
Table 15.74 Bioavailability Studies: Masking of Study
Table 15.75 Bioavailability Studies: Clinical Trials Distribution
Table 15.76 Bioavailability Studies: Trial Status Wise Distribution
Table 15.77 Bioavailability Studies: Distribution of Types of Molecule by Phase of Development
Table 15.78 Bioavailability Studies: Leading Players
Table 15.79 Demand Analysis: Enhanced Formulation Drug Approvals (2010-2015)
Table 15.80 Demand Analysis: Likelihood of Approval
Table 15.81 Demand Analysis: Distribution by Dosage Forms
Table 15.82 Demand Analysis: Phase wise BCS Distribution of Drugs (2018)
Table 15.83 Demand Analysis: Expected Phase wise BCS Distribution of Drugs (2030)
Table 15.84 Demand Analysis: Expected Demand (NCEs)
Table 15.85 Demand Analysis: Expected Demand (NCEs), Opportunity Segmentation by Technology (2025-2030)
Table 15.86 Demand Analysis: BCS for Generic Drugs, 2013 Scenario
Table 15.87 Demand Analysis: BCS for Generic Drugs, 2018 Scenario
Table 15.88 Demand Analysis: BCS for Generic Drugs, 2030 Scenario
Table 15.89 Demand Analysis: Expected Demand (Generic Drugs)
Table 15.90 Bioavailability Enhancement Market: Trends in Bioavailability Enhancement Cost, 2018-2030 (USD Million)
Table 15.91 Bioavailability Enhancement Market: Drugs Adopting Out-Licensing Approach for Bioavailability Enhancement
Table 15.92 Overall Bioavailability Enhancement Market, 2018-2030: Conservative Scenario (USD Billion)
Table 15.93 Overall Bioavailability Enhancement Market, 2018-2030: Base Scenario (USD Billion)
Table 15.94 Overall Bioavailability Enhancement Market, 2018-2030: Optimistic Scenario (USD Billion)
Table 15.95 Bioavailability Enhancement Market: Segmentation by BCS Classification, 2018-2030: Conservative Scenario (USD Billion)
Table 15.96 Bioavailability Enhancement Market: Segmentation by BCS Classification, 2018-2030: Base Scenario (USD Billion)
Table 15.97 Bioavailability Enhancement Market: Segmentation by BCS Classification, 2018-2030: Optimistic Scenario (USD Billion)
Table 15.98 Bioavailability Enhancement Market: Market Shares of Formulation Approaches, (2018, 2025, 2030)
Table 15.99 Bioavailability Enhancement Market: Segmentation by Formulation Approaches, 2018-2030: Conservative Scenario (USD Billion)
Table 15.100 Bioavailability Enhancement Market: Segmentation by Formulation Approaches, 2018-2030: Base Scenario (USD Billion)
Table 15.101 Bioavailability Enhancement Market: Segmentation by Formulation Approaches, 2018-2030: Optimistic Scenario (USD Billion)
Table 15.102 Bioavailability Enhancement Market: Segmentation by Geographical Location, 2018-2030: Conservative Scenario (USD Billion)
Table 15.103 Bioavailability Enhancement Market: Segmentation by Geographical Location, 2018-2030: Base Scenario (USD Billion)
Table 15.104 Bioavailability Enhancement Market: Segmentation by Geographical Location, 2018-2030: Optimistic Scenario (USD Billion)

List of Figures
Figure 3.1 Biopharmaceutical Classification System
Figure 3.2 Biopharmaceutical Classification System: Change in Trends
Figure 3.3 Bioavailability Enhancement Technologies: Evolutionary Timeline
Figure 3.4 Different Designs to Study Drug Bioavailability
Figure 3.5 Single Dose Study to Evaluate Bioavailability
Figure 3.6 Multiple Dose Study to Evaluate Bioavailability
Figure 3.7 Bioavailability Assessment: Methodologies
Figure 3.8 Bioavailability Assessment: Factors Affecting Bioavailability
Figure 3.9 Solid Dispersion: Classifications
Figure 3.10 Solid Dispersion: Preparation Methodologies
Figure 3.11 Solid Dispersion: List of Drugs Prepared by Hot Melt Extrusion
Figure 3.12 Solid Dispersion: List of Drugs Prepared by Melting / Fusion
Figure 3.13 Solid Dispersion: List of Drugs Prepared by Solvent Evaporation
Figure 3.14 Solid Dispersion: List of Drugs Prepared by Spray-Dried Dispersion
Figure 3.15 Solid Dispersion: Melt Agglomeration Technique
Figure 3.16 Nanosuspension: Preparation Methodologies
Figure 3.17 Lipid Based Formulations: Classification
Figure 3.18 Biological Formulation Technologies
Figure 4.1 Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Approach and Geography
Figure 4.2 Bioavailability Enhancement Service Providers: Geographical Landscape
Figure 4.3 Bioavailability Enhancement Service Providers: Distribution by Company Size
Figure 4.4 Bioavailability Enhancement Service Providers: Cumulative Distribution by Year of Establishment
Figure 4.5 Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Principle
Figure 4.6 Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Approach
Figure 4.7 Bioavailability Enhancement Service Providers: Distribution by Lipid Based Approaches
Figure 4.8 Bioavailability Enhancement Service Providers: Distribution by Size Reduction Approaches
Figure 4.9 Bioavailability Enhancement Service Providers: Distribution by Solid Dispersion Based Approaches
Figure 4.10 Bioavailability Enhancement Service Providers: Distribution by Other Formulation Approaches
Figure 4.11 Bioavailability Enhancement Service Providers: Distribution by Dosage Form
Figure 4.12 Bioavailability Enhancement Service Providers: Distribution by Route of Administration
Figure 4.13 Bioavailability Enhancement Service Providers: Heat Map Analysis by Dosage Form and Bioavailability Enhancement Approaches
Figure 4.14 Bioavailability Enhancement Service Providers: Leading Players
Figure 4.15 Bioavailability Enhancement Service Providers: Dosage Form Wise Global Distribution of Leading Players
Figure 5.1 Lonza: Annual Revenues, 2013-2017 (CHF Billion)
Figure 5.2 Lonza: Custom Contract Manufacturing Services
Figure 5.3 Lonza: Bioavailability Enhancement Services Portfolio
Figure 5.4 Catalent: Annual Revenues, 2013- 2017 (USD Billion)
Figure 5.5 Catalent: Revenues by Product Types, 2017 (USD Million)
Figure 5.6 Catalent: Services Portfolio
Figure 5.7 Catalent: Bioavailability Enhancement Services Portfolio
Figure 5.8 Ascendia Pharmaceuticals: Services Portfolio
Figure 5.9 Ascendia Pharmaceuticals: Bioavailability Enhancement Services Portfolio
Figure 5.10 Particle Sciences: Services Portfolio
Figure 5.11 Particle Sciences: Bioavailability Enhancement Services Portfolio
Figure 5.12 Juniper Pharmaceuticals: Annual Revenues, 2013-2017 (USD Million)
Figure 5.13 Juniper Pharma Services: Services Portfolio
Figure 5.14 Juniper Pharma Services: Bioavailability Enhancement Services Portfolio
Figure 5.15 Phosphorex: Polymeric Nanoparticles Applications
Figure 5.16 Phosphorex: Bioavailability Enhancement Services Portfolio
Figure 5.17 Kuecept: Services Portfolio
Figure 5.18 Kuecept: Bioavailability Enhancement Services Portfolio
Figure 5.19 Creative Biolabs: Services Portfolio
Figure 5.20 Creative Biolabs: Bioavailability Enhancement Services Portfolio
Figure 5.21 WuXi AppTec: Annual Revenues, 2010-Q3 2015 (USD Million)
Figure 5.22 WuXi AppTec: Services Portfolio
Figure 5.23 WuXi AppTec: Bioavailability Enhancement Services Portfolio
Figure 6.1 Benchmark Analysis: Distribution of Industry Players by Year of Establishment and Geographical Location
Figure 6.2 Benchmark Analysis: American Companies, Peer Group I
Figure 6.3 Benchmark Analysis: American Companies, Peer Group II
Figure 6.4 Benchmark Analysis: American Companies, Peer Group III
Figure 6.5 Benchmark Analysis: European Companies, Peer Group IV
Figure 6.6 Benchmark Analysis: European Companies, Peer Group V
Figure 6.7 Benchmark Analysis: European Companies, Peer Group VI
Figure 6.8 Benchmark Analysis: Asian Companies, Peer Group VII
Figure 6.9 Benchmark Analysis: Asian Companies, Peer Group VIII
Figure 7.1 Bioavailability Enhancement Partnerships: Cumulative Year-wise Trend
Figure 7.2 Bioavailability Enhancement Partnerships: Distribution by Type of Collaboration
Figure 7.3 Bioavailability Enhancement Partnerships: Yearly Distribution by Type of Collaboration
Figure 7.4 Bioavailability Enhancement Partnerships: Distribution by Most Active Players
Figure 7.5 Bioavailability Enhancement Partnerships: Distribution by Key Acquirers
Figure 7.6 Bioavailability Enhancement Partnerships: Distribution by Key Acquirers
and Year of Acquisitions
Figure 8.1 Bioavailability Enhancement Publications: Cumulative Year-Wise Trend
Figure 8.2 Bioavailability Enhancement Publications: Top 15 Journals
Figure 8.3 Bioavailability Enhancement Publications: Emerging Areas
Figure 8.4 Bioavailability Enhancement Publications: Distribution of Approaches by Number of Publications
Figure 8.5 Bioavailability Enhancement Publications: Distribution of Approaches by Year of Publication
Figure 8.6 Bioavailability Enhancement Publications: Distribution of Approaches by CAGR (2008-2017)
Figure 8.7 Bioavailability Enhancement Publications: Technology Wise Bubble Chart Analysis

Figure 9.1 Bioavailability Enhancement Patents: Distribution by Type of Patent
Figure 9.2 Bioavailability Enhancement Patents: Distribution by Type of Technology
Figure 9.3 Bioavailability Enhancement Patents: Cumulative Distribution by Year and Bioavailability Enhancement Approach
Figure 9.4 Bioavailability Enhancement Patents: Distribution by Patent CAGR and Bioavailability Enhancement Approach
Figure 9.5 Bioavailability Enhancement Patents: Distribution by Publication Year
Figure 9.6 Bioavailability Enhancement Patents: Year-wise Regional Distribution
Figure 9.7 Bioavailability Enhancement Patents: Cumulative Distribution by CPC Classification Symbol
Figure 9.8 Bioavailability Enhancement Patents: Emerging Areas
Figure 9.10 Bioavailability Enhancement Patents: Age of Patent
Figure 9.11 Bioavailability Enhancement Patents: Patent Valuation
Figure 9.12 Bioavailability Enhancement Patents: Geographical Patent Valuation
Figure 9.13 Bioavailability Enhancement Patents: Leading Players
Figure 10.1 Bioavailability Studies: Cumulative Year Wise Trend
Figure 10.2 Bioavailability Studies: Study Design
Figure 10.3 Bioavailability Studies: Clinical Trial Distribution
Figure 10.4 Bioavailability Studies: Trial Status Wise Distribution
Figure 10.5 Bioavailability Studies: Distribution of Molecules by Phase of Development
Figure 10.6 Bioavailability Studies: Leading Players
Figure 10.7 Bioavailability Studies: Study Focus
Figure 11.1 Demand Analysis: Enhanced Formulation Drug Approvals (2010-2015)
Figure 11.2 Demand Analysis: Likelihood of Approval
Figure 11.3 Demand Analysis: Distribution by Dosage Forms
Figure 11.4 Demand Analysis: Distribution of Types of Molecule by Phase of Development
Figure 11.5 Demand Analysis: Expected Phase wise BCS Distribution of Drugs (2030)
Figure 11.6 Demand Analysis: Expected Demand (NCEs)
Figure 11.7 Demand Analysis: Expected Demand (NCEs), Opportunity Segmentation by Technology (2025-2030)
Figure 11.8 Demand Analysis: Expected Demand (Generics)
Figure 11.9 Demand Analysis: Expected Demand (Generics), Opportunity Segmentation by Technology (2025-2030)
Figure 12.1 Bioavailability Enhancement Market: Cost of Bioavailability Enhancement,
Figure 12.2 Bioavailability Enhancement Market: Trends in Out-Sourcing
Figure 12.3 Overall Bioavailability Enhancement Market, 2018-2030: Base Scenario (USD Billion)
Figure 12.4 Bioavailability Enhancement Market: Segmentation by BCS Classification, 2018-2030: Base Scenario (USD Billion)
Figure 12.5 Bioavailability Enhancement Market: Market Shares of Formulation Approaches, (2018, 2025, 2030)
Figure 12.6 Bioavailability Enhancement Market: Segmentation by Formulation Approaches, 2018-2030: Base Scenario (USD Billion)
Figure 12.7 Bioavailability Enhancement Market: Segmentation by Geographical Location, 2018-2030: Base Scenario (USD Billion)

The following companies / institutes / government bodies and organizations have been mentioned in this report.
1. Abbott
2. AbbVie Contract Manufacturing
3. ABITEC
4. Accu-Break Pharmaceuticals
5. Aché Laboratórios Farmacêuticos
6. Acorn Biomedical
7. Actavis
8. Adare Pharmaceuticals
9. Admas Pharmaceuticals
10. Aegis Therapeutics
11. Aesica
12. Agere Pharmaceuticals
13. Aizant Drug Research Solutions
14. Ajinomoto
15. Alcami
16. Alexion Pharmaceuticals
17. Alkermes
18. Allergan
19. Alliance Contract Pharma
20. Almac Group
21. Althea Technologies
22. Altum Pharmaceuticals
23. Altus Formulation
24. Amatsigroup
25. AMRI
26. Applied Manufacturing Science
27. Aquestive Therapeutics
28. Arbro Pharmaceuticals
29. Arbutus Biopharma
30. Ardena Group
31. Ascendia Pharmaceuticals
32. Ashland
33. Athenex
34. Avara Pharmaceutical Services
35. Avro Pharma
36. Avomeen Analytical Services
37. BASF
38. Baxter International
39. BEC Chemicals
40. Bend Research
41. BioConnection
42. BioDuro
43. Bionpharma
44. Bio-serv
45. Bridgepoint Development Capital
46. Calando Pharmaceuticals
47. Calvert Laboratories
48. Camurus
49. Capsugel
50. Catalent
51. CEPiA Sanofi
52. Cerenis Therapeutics
53. ChemConnection
54. Chiasma Pharma
55. Co-Formulate
56. Colorcon
57. Continuous Technologies International
58. Corazon
59. COREALIS Pharma
60. CoreRx
61. Creative Biolabs
62. CritiTech
63. Croda International
64. Crystal Pharmatech
65. Crystallics
66. CrystecPharma
67. CuriRx
68. Cyclolab
69. Cyndea Pharma
70. Cytec
71. Dalton Pharma Services
72. Dauntless Pharmaceuticals
73. DisperSol Technologies
74. Dow Pharma Solutions
75. Eagle Pharmaceuticals
76. École Polytechnique Fédérale de Lausanne
77. Emisphere Technologies
78. Emmerson Resources
79. Entera Bio
80. Enteris BioPharma
81. Evonik Health Care
82. Evotec
83. ExxPharma Therapeutics
84. Ferring Pharmaceuticals
85. Forest Laboratories
86. Formac Pharmaceuticals
87. Formex
88. Foster Delivery Science
89. Friulchem
90. Fuji Chemical Industries
91. Gattefossé
92. Generex Biotechnology
93. GenPlus
94. Glatt Integrated Process Solutions
95. Glenmark Pharmaceuticals
96. GP Pharm
97. GVK Biosciences
98. Halo Pharma
99. Harvard University
100. Helix BioPharma
101. Hovione
102. IACTA Pharmaceuticals
103. iCeutica
104. IMCD
105. Indena
106. Industrias Biocontrolled
107. Instillo Group
108. Intas Pharmaceuticals
109. Intec Pharma
110. Jamia Hamdard University
111. Jetpharma
112. Jina Pharmaceuticals
113. Juniper Pharma Services
114. Keystone Nano
115. Kinex Pharmaceuticals
116. Kuecept
117. LATITUDE Pharmaceuticals
118. leon-nanodrugs
119. Lexaria Bioscience
120. Ligand Pharmaceuticals
121. Lipomize
122. Lonza
123. Losan Pharma
124. Lubrizol
125. Lypro Biosciences
126. Marinus Pharmaceuticals
127. Matinas BioPharma
128. Merrion Pharmaceuticals
129. Metrics Contract Services
130. MicroChem
131. Microfine Pharma
132. Micro-Macinazione
133. Micro-Sphere
134. Midas Pharma
135. MIKA PHARMACEUTICALS
136. Molecular Profiles
137. Monash University
138. Mutchler
139. Nanocopoeia
140. Nanomaterials
141. Nanomerics
142. Nanosphere Health Sciences
143. Natco Pharma
144. Nemus Bioscience
145. NETZSCH Premier Technologies
146. NeutriSci Internatinal
147. New York Center for Nanomedicine Research
148. Nippon Soda
149. Nisso America
150. NMT Pharmaceuticals
151. Nordic Bioscience
152. Novaliq
153. Novartis Pharmaceuticals
154. Novo Nordisk
155. Novozymes
156. Nuformix Technologies
157. Oasmia Pharmaceutical
158. Okklo Life Sciences
159. Opiant Pharmaceuticals

Please contact our Customer Support Center to get the complete Table of Contents